P14.108 Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

BACKGROUND: The use of alkylating chemotherapy versus bevacizumab for recurrent glioblastoma remains controversial. Here we tested the hypothesis that the activity of alkylators, but not that of bevacizumab, would be associated with the O(6)-methylguanine DNA methyltransferase (MGMT) promoter methyl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Seystahl, K, Hentschel, B, Loew, S, Gramatzki, D, Felsberg, J, Herrlinger, U, Westphal, M, Schackert, G, Thon, N, Schlegel, U, Tatagiba, M, Pietsch, T, Reifenberger, G, Löffler, M, Wick, W, Weller, M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Poster Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.343
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados